AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

Sales and UpgradesContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

13 Sep
AHFS Drug Information logo
AHFS September 2022 Update

This update contains 2 new monographs and 16 revised monographs.

New monographs: Ganaxolone; Vutrisiran

Revised monographs: Alectinib; Bosutinib; Cabozantinib; Decitabine and Cedazuridine, Erdafitinib, Inotersen, Lanreotide; Lemborexant; Osimertinib; Patisiran; romiPLOStim; Ruxolitinib; Sarilumab; SORAfenib; Suvorexant; Tecovirimat.

09 Aug
AHFS Drug Information logo
AHFS August 2022 Update

This update contains 14 revised monographs and 2 new MedWatch alerts.

Revised monographs: Abemaciclib; Anakinra; COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Pfizer-BioNTech); Elbasvir and Grazoprevir; Ixekizumab; Larotrectinib; Lorlatinib; Pexidartinib; Semaglutide; Trifluridine and Tipiracil; Ustekinumab; Vandetanib; Vemurafenib

New MedWatch alerts on the following monographs: Duvelisibl; Umbralisib

12 Jul
AHFS Drug Information logo
AHFS July 2022 Update

This update contains 3 new monographs and 16 revised monographs.

New monographs: Sirolimus (Topical); Daridorexant; Mavacamten

Revised monographs: SUNItinib; Cabergoline; Enzalutamide; Trametinib Dimethyl Sulfoxide; Rotigotine; Secukinumab; Galcanezumab-gnlm; Tafamidis; Alpelisib; Elexacaftor, Tezacaftor, and Ivacaftor; Ubrogepant; Cenobamate; Ozanimod; Selumetinib; Atogepant; rOPINIRole

14 Jun
AHFS Drug Information logo
AHFS June 2022 Update

This update contains 15 revised monographs.

Revised monographs: Aducanumab; Apomorphine; Afatinib; Axitinib; Baricitinib; Bromocriptine; Fingolimod; Golimumab; Guselkumab; Pemigatinib; Ponesimod; Regorafenib; Ribociclib; Risankizumab-rzaa; Tofacitinib.

10 May
AHFS Drug Information logo
AHFS May 2022 Update

This update contains 2 new monographs and 25 revised monographs.

New monographs: Nivolumab and Relatlimab-rmbw; Pacritinib

Revised monographs: Acalabrutinib; Adalimumab; Brigatinib; Brodalumab; Certolizumab; COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Pfizer-BioNTech); Eptinezumab-jjmr; Erenumab-aooe; Fremanezumab-vfrm; Glatiramer; Imatinib; Infigratinib; Lanadelumab; Lurbinectedin; Nilotinib; Nitroglycerin; PAZOPanib; Pramipexole; Rimegepant; Sotrovimab; Teduglutide; Tivozanib; Trihexyphenidyl; Upadacitinib

08 Apr
AHFS Drug Information logo
AHFS April 2022 Update

This update contains 3 new monographs and 61 revised monographs.

New monographs: Abrocitinib; Bebtelovimab; Faricimab

Revised monographs: Alprostadil; Alteplase; Amantadine; Amiodarone; Apremilast; Argatroban; Asparaginase (Erwinia chrysanthemi) (recombinant)-rywn; Avatrombopag; Belzutifan; Benztropine; Bumetanide; Cisatracurium; Dasatinib; Dexmedetomidine; dilTIAZem; Diroximel Fumarate; DOBUTamine; Dopamine; Dostarlimab-gxly; Eltrombopag; Epinephrine; Esmolol; Etanercept; fentaNYL; Furosemide; Heparin; HYDROmorphone; Ibrutinib; Insulin Human; Isoproterenol; Ketamine; Labetalol; LORazepam; Midazolam; Milrinone; Morphine; Naloxone; niCARdipine; Norepinephrine; Octreotide; Osimertinib; Pantoprazole; PENTobarbital; Phenylephrine; Pralsetinib; Propofol; Remifentanil; Ripretinib; Rocuronium; Sodium Bicarbonate; Sodium Chloride; Sodium Nitroprusside; Sonidegib; Temozolomide; Tepotinib; Terbutaline; Tranexamic Acid; Umbralisib; Vasopressin; Vecuronium; Venetoclax

View more View all content updates